We analysed the effects of baseline characteristics on the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) from two phase III trials.In RA-BEAM (NCT01710358), patients with inadequate response to methotrexate were randomised to placebo, baricitinib 4?mg or adalimumab 40?mg. RA-BUILD (NCT01721057) patients had inadequate response to =1?csDMARDs and were randomised to either placebo or once-daily baricitinib (2 or 4?mg). Both study populations were naïve to biologic DMARDs (bDMARDs). Primary end point for both studies was American College of Rheumatology 20% improvement (ACR20) response at week 12. Pooled data from the two trials were analysed post hoc based on select subgroups defined by age, previous csDMARD use, baseline RA disease activity, etc, with assessment of clinical and safety outcomes at week 12 and radiographic outcomes at week 24 for the baricitinib 4?mg and placebo-treated patients.Efficacy was observed with baricitinib 4?mg treatment irrespective of patient demographics and baseline disease characteristics. ORs primarily favoured baricitinib over placebo in the ACR20 response. In other outcomes such as Disease Activity Score for 28 joints based on high-sensitivity C reactive protein levels, Simplified Disease Activity Index score =11 and radiographic progression, baricitinib 4?mg showed better responses than placebo regardless of baseline characteristics. Safety events were more common in patients over 65 years, but similar between baricitinib 4?mg and placebo patients.Baseline characteristics did not substantially affect clinical response to baricitinib 4?mg in patients with RA with inadequate response to csDMARDs.
View details for DOI 10.1136/rmdopen-2017-000581
View details for PubMedID 29479473
View details for PubMedCentralID PMC5822634